EXAS vs. NTRA, EXEL, LH, FTRE, RDNT, INCY, PODD, DVA, RDY, and UHS
Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Natera (NTRA), Exelixis (EXEL), Laboratory Co. of America (LH), Fortrea (FTRE), RadNet (RDNT), Incyte (INCY), Insulet (PODD), DaVita (DVA), Dr. Reddy's Laboratories (RDY), and Universal Health Services (UHS). These companies are all part of the "medical" sector.
Natera (NASDAQ:NTRA) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Natera has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Exact Sciences has higher revenue and earnings than Natera. Exact Sciences is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.
Exact Sciences has a net margin of -8.17% compared to Exact Sciences' net margin of -40.16%. Natera's return on equity of -6.60% beat Exact Sciences' return on equity.
Exact Sciences received 495 more outperform votes than Natera when rated by MarketBeat users. Likewise, 72.40% of users gave Exact Sciences an outperform vote while only 68.59% of users gave Natera an outperform vote.
In the previous week, Natera had 16 more articles in the media than Exact Sciences. MarketBeat recorded 21 mentions for Natera and 5 mentions for Exact Sciences. Natera's average media sentiment score of 1.01 beat Exact Sciences' score of 0.32 indicating that Exact Sciences is being referred to more favorably in the news media.
99.9% of Natera shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 9.4% of Natera shares are held by insiders. Comparatively, 1.3% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Natera currently has a consensus price target of $86.40, indicating a potential downside of 5.74%. Exact Sciences has a consensus price target of $97.44, indicating a potential upside of 65.57%. Given Natera's higher probable upside, analysts clearly believe Exact Sciences is more favorable than Natera.
Summary
Exact Sciences beats Natera on 10 of the 18 factors compared between the two stocks.
Get Exact Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exact Sciences Competitors List
Related Companies and Tools
